The Janus kinase (JAK) family (JAK1, JAK2, JAK3 and tyrosine kinase-2 [TYK2]) of non-receptor tyrosine kinases are implicated in the pathogenesis of RA, and are considered a promising target for RA treatment [7, 8]. Here, JAK2 is linked to rheumatoid arthritis.